Neuromeningeal Tuberculosis in a Patient with Rheumatoid Arthritis Previously Exposed to Ineffective Etanercept Therapy and Revealed by Infliximab

To the Editor:

We describe the case of a 74-year-old French Caucasian woman, born in Nice, a former storekeeper, with a history of seropositive and erosive rheumatoid arthritis (RA) dating from 1993. She had been treated unsuccessfully (inefficacy or severe side effects) with hydroxychloroquine, methotrexate, and leflunomide. In February 2002, she was given infliximab 3 mg/kg/8 weeks in combination with leflunomide 20 mg per day. Hepatic cytolysis necessitated discontinuation in February 2005. Etanercept alone was tried for 7 months, also unsuccessfully. The hepatic cytolysis was subsequently attributed to the use of nonsteroidal antiinflammatory drugs. In October 2005, infliximab was introduced (5 mg/kg/8 wks) in association with leflunomide (10 mg/day) without glucocorticoids.

In September 2006, she was admitted to our department with headache, tiredness, equilibrium disturbances, and a clinical cerebellar syndrome. Treatment was discontinued but, 24 h later, right flaccid hemiplegia appeared with dysarthria. Brain computed tomography scan showed a pattern of cerebrovascular ischemic accident, and she was treated with low molecular weight heparin plus platelet antiaggregants. The motor deficiency was resolved within a few days, but temporospatial disorientation and dyscalculia persisted, particularly when the agent is infliximab. Several theories have been put forward to explain the lower frequency of TB reactivation with etanercept. Factors include differences in mechanism of action, infliximab's longer half-life, and the greater popularity of infliximab. Infliximab binds both soluble and transmembrane TNF, whereas etanercept has a lower binding affinity for the latter. In the context of TB, the implication is that infliximab disrupts granuloma integrity, because 100% neutralization of TNF invariably results in severely diminished inflammatory cell recruitment. Consequently, the high turnover of cells within the dynamic granuloma can no longer be maintained. Etanercept may be thought of as partially preserving granuloma integrity, because it allows redistribution of bioactive TNF from sites of production such as the rheumatoid joint into other tissues, where overall, TNF concentrations are low. TNF bioactivity may therefore not be entirely blocked, thus preserving the residual antimicrobial function of macrophages in granulomatous lesions. Monoclonal antibodies such as infliximab activate complement and cause antibody-dependent cellular toxicity. In the context of TB, lysed granuloma macrophages would release mycobacteria into the bloodstream, potentially explaining the relatively high occurrence of disseminated TB in infliximab-treated patients. Etanercept has no reported apoptosis-inducing effect. TNF neutralization persists for several weeks with infliximab, compared with several days with etanercept, which allows minimal TNF activity between injections. Preservation of 10%-30% of total TNF activity provides sufficient antimicrobial effect to minimize resurgence of TB and help maintain the stability of RA. This can be an explanation for the lower frequency of TB reactivation with etanercept.

Widespread dissemination of recommendations has resulted in a decrease in the number of cases of TB. Our patient was given infliximab before the publication of these recommendations, so TST and chest radiography were performed a few months later and were negative.
TST remains the only tool available for rapid TB screening. Unfortunately, false-negative results are common (particularly among immunocompromised and severely sick patients). According to one study, anti-TNF treatment can enhance the diagnostic value of the test by improving the anergic status associated with active arthritis. Observation of skin test-negative patients receiving anti-TNF therapy supports repeating the test in order to improve identification of patients requiring isoniazid treatment; for this reason, recommendations include 2-step TST with an interval of 7–10 days between steps. Against that background, TB-specific antigens (CFP10, ESAT6) have been suggested for the past few years. They seem to be more specific for TB screening (overall, ESAT6 and CFP10 have 73% sensitivity and 95% specificity) with a similar sensitivity in active TB with TST. But they do not permit differentiating latent from active forms.

This case of TB induced by anti-TNF therapy has several exceptional features: very rare localizations in the brain of TB granuloma with a clinical pattern of tuberculous meningoencephalitis, the long interval between the introduction of biologic agents and the development of TB, which seems to be more in favor of a primary infection. But it is not possible to know whether TB was a reactivation of latent TB or primary infection, because the TST was not performed previously but during biologic treatment. This emphasizes the risk of development of serious forms of TB with biologic agents and the need to be aware of unusual presentations of TB among patients treated with TNF antagonists.

VIRGINIE DaSILVA, MD, University Hospital, Rheumatology; CHRISTIAN H. ROUX, MD, Academic Hospital l’Archet 1, Service de Rhumatologie; EVELYNE BERNARD, MD, University Hospital, Infectious Diseases; OLIVIER BROCQ, MD, CHRISTINE ALBERT, MD; HASNA CHAMI, MD; CHRISTIAN GRISOT, MD; YACINE ALLAM, MD, University Hospital, Rheumatology; PIERRE DELLAMONICA, MD, University Hospital, Infectious Diseases; LIANA EULLER-ZIEGLER, MD, University Hospital, Rheumatology, Nice, France. Address correspondence to Dr. Da Silva. E-mail: dasilva.v@chu-nice.fr

REFERENCES

J Rheumatol 2010;37:2; doi:10.3899/jrheum.090241